XML 35 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Apr. 30, 2018
Mar. 31, 2020
Mar. 31, 2019
Loss Contingencies [Line Items]      
Operating leases, rent expense   $ 60,000 $ 27,000
Teva Agreements      
Loss Contingencies [Line Items]      
Nonrefundable upfront payment $ 6,000,000    
Payment upon achievement of certain clinical and commercial milestones 135,000,000    
Asset transfer and license agreement, termination period after written notice     120 days
Asset transfer and license agreement, termination period notice of breach     60 days
Asset transfer and license agreement termination notice period if bankruptcy petition filed     60 days
Teva Agreements | Research and Development Expenses      
Loss Contingencies [Line Items]      
Up-front license payment   $ 0 $ 0
Teva Agreements | Teva’s GlycoPEGylated FGF21 Program      
Loss Contingencies [Line Items]      
Payment upon achievement of certain clinical and commercial milestones 67,500,000    
Teva Agreements | Teva’s Development Program      
Loss Contingencies [Line Items]      
Payment upon achievement of certain clinical and commercial milestones $ 67,500,000